|
A Safety Study of Escalating Doses of PRO70769 for Subjects with Moderate to Severe Rheumatoid Arthritis Receiving Stable Doses of Concomitant Methotrexate Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or professional assistance by using a genuine doctor. We aren't mDs. Always consult your physician about A Safety Study of Escalating Doses of PRO70769 for Subjects with Moderate to Severe Rheumatoid Arthritis Receiving Stable Doses of Concomitant Methotrexate conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. A Safety Study of Escalating Doses of PRO70769 for Subjects with Moderate to Severe Rheumatoid Arthritis Receiving Stable Doses of Concomitant Methotrexate Clinical research trials and A Safety Study of Escalating Doses of PRO70769 for Subjects with Moderate to Severe Rheumatoid Arthritis Receiving Stable Doses of Concomitant Methotrexate health trials occur in a lot of of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the potency of new does drugs. The role of the studies / undertakings is to figure out specific human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all sorts of conditions, including A Safety Study of Escalating Doses of PRO70769 for Subjects with Moderate to Severe Rheumatoid Arthritis Receiving Stable Doses of Concomitant Methotrexate. A Safety Study of Escalating Doses of PRO70769 for Subjects with Moderate to Severe Rheumatoid Arthritis Receiving Stable Doses of Concomitant Methotrexate Clinical Trials and other clinical trials permit volunteers to get medical treatment choices before they are available to the general public. Many times the test subjects get professional assistance for free of charge, and occasionally they are compensated for their time. Sometimes there is a cost for a A Safety Study of Escalating Doses of PRO70769 for Subjects with Moderate to Severe Rheumatoid Arthritis Receiving Stable Doses of Concomitant Methotrexate clinical trial. Human subjects often get the best healthcare possible for their A Safety Study of Escalating Doses of PRO70769 for Subjects with Moderate to Severe Rheumatoid Arthritis Receiving Stable Doses of Concomitant Methotrexate condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, medical hazards (perhaps life-threatening), and/or the treatment being ineffectual. Trials are federally governed with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Safety Study of Escalating Doses of PRO70769 for Subjects with Moderate to Severe Rheumatoid Arthritis Receiving Stable Doses of Concomitant Methotrexate A Safety Study of Escalating Doses of PRO70769 for Subjects with Moderate to Severe Rheumatoid Arthritis Receiving Stable Doses of Concomitant Methotrexate
A Safety Study of Escalating Doses of PRO70769 for Subjects with Moderate to Severe Rheumatoid Arthritis Receiving Stable Doses of Concomitant Methotrexate
For Condition: Rheumatoid Arthritis
Status: Recruiting
Sponsor(s): Genentech ,
Synopsis: The purpose of this study is to determine the safe dose of PRO70769 for subjects with moderate to severe rheumatoid arthritis receiving stable doses of concomitant methotrexate.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/80 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Ability and willingness to provide written informed consent and to comply with the requirements of the protocol - Diagnosis of RA for at least 6 months according to the revised 1987 ACR criteria for the classification of RA - Positive serum RF - Current treatment for RA on an outpatient basis Contact your local site that is listed for more inclusion criteria Exclusion Criteria: - Bone or joint surgery (including joint fusion) within 8 weeks prior to screening or joint surgery planned within 24 weeks after randomization - Rheumatic autoimmune disease other than RA or significant systemic involvement secondary to RA (e.g., vasculitis, pulmonary fibrosis, or Felty’s syndrome) - Functional Class IV as defined by the ACR classification of functional status in RA - History of or current inflammatory joint disease other than RA (e.g., gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, Lyme disease) or other systemic rheumatic disorders (e.g., systemic lupus erythematosus, inflammatory bowel disease, scleroderma, inflammatory myopathy, overlap syndrome) Contact your local site that is listed for more exclusion criteria
Total Enrollment:
Location and Contact Information:
Arthritis Associates, PA *Recruiting*
Palm Harbor, Florida, 34684
United States
Recruiting Ginger Pfeiffer 727-210-2555
San Diego Arthritis and Osteoporosis Medical Clinic *Recruiting*
San Diego, California, 92120
United States
Recruiting Christina Henry 619-287-9730
Physician's Research Options, LLC *Recruiting*
Ogden, Utah, 84403
United States
Recruiting Melody Pope 801-387-3665
Rheumatology Associates of North Alabama *Recruiting*
Huntsville, Alabama, 35801
United States
Recruiting Therese Lambert 256-517-6778
CRIA Research *Recruiting*
Ft. Lauderdale, Florida, 33334
United States
Recruiting Karen Herr 954-229-0425
Arthritis Consultants, Inc. *Recruiting*
St. Louis, Missouri, 63141
United States
Recruiting Angela Kean 314-567-5100
Amarillo Center for Clinical Research, Ltd. *Recruiting*
Amarillo, Texas, 79124
United States
Recruiting Jeannette Knowles 806-352-2453
Sarasota Arthritis Research Center *Recruiting*
Sarasota, Florida, 34239
United States
Recruiting Pam McEwen 941-366-1244
Center for Rheumatology and Bone Research *Recruiting*
Wheaton, Maryland, 20902
United States
Recruiting Susan Chandler 301-942-6610
Arthritis and Osteoporosis Associates, LLP *Recruiting*
Lubbock, Texas, 79410
United States
Recruiting Brenda Parrish 806-771-7040
Coastal Medical Research *Recruiting*
Port Orange, Florida, 32127
United States
Recruiting Jackie Boucher 386-304-7070
University of Arizona *Recruiting*
Tucson, Arizona, 85724
United States
Recruiting Oscar Furet 520-626-2592
Kentuckiana Center for Better Bone and Joint Health *Recruiting*
Louisville, Kentucky, 40202
United States
Recruiting Terri Jordan 502-569-1050
Seligman Center for Advanced Therapeutics, Dept of Rheumatology and Medicine *Recruiting*
New York City, New York, 10003
United States
Recruiting Eileen McCullagh 646-356-9406
University of Chicago *Recruiting*
Chicago, Illinois, 60637
United States
Recruiting Shahnaz Kazi 773-702-2645
Portland Medical Associates *Recruiting*
Portland, Oregon, 97224
United States
Recruiting Shiralynn Moore 503-620-2117
Austin Rheumatology Research, PA *Recruiting*
Austin, Texas, 78705
United States
Recruiting Leah Belew 512-380-9988
Additional Information:
Study ID Numbers: ACT2847g;
Study Start Date:
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00077870
Other Rheumatoid Arthritis Studies:
1. Study to Assess Efficacy of Tacrolimus + Methotrexate Vs. Placebo + Methotrexate in Treatment of Rheumatoid Arthritis
2. Oral Collagen for Rheumatoid Arthritis
3. Safety Study for Remicade
4. Genetic and Immune Studies of Rheumatoid Arthritis and Related Conditions
5. Treatment of Rheumatoid Arthritis with Marine and Botanical Oils
Related Studies:
Other Rheumatoid Arthritis Clinical Trials
Other Maryland Clinical Trials
Other Wheaton Clinical Trials
A Safety Study of Escalating Doses of PRO70769 for Subjects with Moderate to Severe Rheumatoid Arthritis Receiving Stable Doses of Concomitant Methotrexate
|
|
|
|
|
|
|
|